Myriad Genetics Inc. (MYGN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Myriad Genetics Inc. (MYGN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

13.68

-0.60 (-4.20%)

At close: Jan 14, 2025, 3:59 PM

13.73

0.37%

After-hours Jan 14, 2025, 07:54 PM EST

undefined% (undefined)

Bid	12.8
Market Cap	1.25B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.28
PE Ratio (ttm)	-10.69
Forward PE	n/a
Analyst	Hold

Ask	21.88
Volume	543,995
Avg. Volume (20D)	963,304
Open	14.33
Previous Close	14.28
Day's Range	13.26 - 14.50
52-Week Range	12.87 - 29.30
Beta	undefined

About MYGN

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Oct 6, 1995

Employees 2,700

Stock Exchange NASDAQ

Ticker Symbol MYGN

Website https://myriad.com

Analyst Forecast

According to 11 analyst ratings, the average rating for MYGN stock is "Hold." The 12-month stock price forecast is $21, which is an increase of 53.51% from the latest price.

Buy 27.27%

Hold 45.45%

Sell 27.27%

Stock Forecasts

Next Earnings Release

Myriad Genetics Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $213.34M, reflecting a 8.51% YoY growth and earnings per share of 0.03, making a -25.00% decrease YoY.

Why Price Moved

4 months ago · Source

-7.65%

Myriad Genetics shares are trading lower after the... Unlock content with Pro Subscription

News

5 days ago · zacks.com

MYGN Stock Gains Following Collaboration With Hannah Storm

Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program ambassador.

3 weeks ago · zacks.com

MYGN Stock Might Gain From the New Recognition of RiskScore Study

The American Journal of Human Genetics names Myriad Genetics' RiskScore study as one of the top 10 significant advances in genomic medicine.

4 weeks ago · zacks.com

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.

1 month ago · zacks.com

New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?

Myriad Genetics' Prolaris test reinforced as an 'Advanced Tool' by the NCCN for prognostic assessment.

1 month ago · zacks.com

MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2

Myriad Genetics incorporates its proprietary HRD platform in Illumina's updated TruSight Oncology 500 v2 comprehensive gene panel assay.

2 months ago · businesswire.com

MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $MYGN #MYGN--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the...

2 months ago · zacks.com

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores

Myriad Genetics announces the availability of SneakPeek - the first at-home early fetal sex test in Walmart, Walgreens and CVS stores nationwide.

2 months ago · seekingalpha.com

Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Transcript

Myriad Genetics, Inc. (NASDAQ:MYGN ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Matt Scalo - Senior Vice President of Investor Relations Paul Diaz - President an...

2 months ago · zacks.com

MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View

Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company increases its full-year EPS guidance.

2 months ago · zacks.com

Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics

The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estim...

2 months ago · zacks.com

Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates

Myriad Genetics (MYGN) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago.

2 months ago · zacks.com

BIIB vs. MYGN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors ...

2 months ago · zacks.com

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

Myriad (MYGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

Myriad Genetics Shares Fall Despite Partnership With jscreen

MYGN partners with jscreen to expand access to high-quality hereditary cancer and reproductive genetics testing for high-risk populations.